Thymopentin is a synthetic pentapeptide corresponding to the active site (amino acids 32-36) of the native thymic hormone thymopoietin. It was discovered and characterized in the 1970s through research aimed at identifying the biologically active regions of thymopoietin responsible for its immunomodulatory effects. This peptide represents a significant advancement in thymic hormone research, as it retains the core immunomodulatory activity of the full-length protein while being small enough for practical synthesis and therapeutic investigation. Its significance lies in its role as a precise immunomodulator, capable of restoring immune function in various states of immunodeficiency without the broad immunosuppressive effects of many other agents, making it a valuable tool for studying T-cell biology and immune system regulation.
Research on thymopentin has demonstrated its ability to modulate T-cell differentiation and function, influencing both cellular and humoral immune responses. It has been extensively studied in clinical and preclinical research for conditions involving immune dysregulation, such as rheumatoid arthritis, chronic viral infections, and secondary immunodeficiencies. The peptide’s targeted action on specific steps of T-cell maturation and activation provides a more refined approach to immune intervention compared to non-specific immunostimulants or immunosuppressants.
Quick Facts
| Also Known As | TP-5, Thymopoietin pentapeptide, Arg-Lys-Asp-Val-Tyr, RKDVY |
|---|---|
| Sequence | Arg-Lys-Asp-Val-Tyr |
| Molecular Formula | C30H49N9O9 |
| Molecular Weight | 679.8 Da |
| PubChem CID | 451417 |
Research Parameters
| Half-Life | Approximately 30-40 minutes following subcutaneous injection in human studies. |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in sterile solvent, the solution should be stored at 2-8°C and used promptly, typically within 24-48 hours to ensure stability and sterility, although specific data on reconstituted stability is limited. |
| Solubility | Recommended reconstitution in sterile water for injection or bacteriostatic water (containing 0.9% benzyl alcohol). It is also soluble in physiological saline (0.9% sodium chloride). |
| Vial Size | 10 mg |
| Storage (Lyophilized) | -20°C or below, protected from light and moisture. For long-term storage, desiccated conditions are recommended. |
| Storage (Reconstituted) | 2-8°C (refrigerated) for short-term storage. Should be used within 24-48 hours after reconstitution. Do not freeze the reconstituted solution. |
| Typical Research Dose | 500 mcg to 5000 mcg (0.5 mg to 5 mg) per injection in research protocols. Doses are often weight-adjusted in animal studies. |
| Cycle Parameters | Research protocols vary widely. A common investigational regimen involves daily subcutaneous injections for 7-14 consecutive days as a loading phase, followed by maintenance injections 2-3 times per week for periods ranging from 4 weeks to several months, depending on the research objective. |
| Amino Acid Count | 5 |
Mechanism of Action
Thymopentin acts as a specific immunomodulator primarily by interacting with T-lymphocytes and their precursors, influencing differentiation, maturation, and functional activity. Its mechanism is multifaceted, targeting key receptors and signaling pathways within the immune system.
Interaction with T-cell Precursors: Thymopentin binds to specific receptors on prothymocytes and immature T-cells, promoting their differentiation into mature, functional T-lymphocytes. This is believed to involve modulation of intracellular cAMP and calcium signaling.
Modulation of T-cell Subsets: The peptide helps restore the balance between helper T-cell (CD4+) and suppressor/cytotoxic T-cell (CD8+) populations. It can enhance the function of deficient subsets, particularly in states of immunosuppression.
Cytokine Regulation: Thymopentin influences the production and release of key cytokines, including interleukin-2 (IL-2), interferon-gamma (IFN-γ), and other Th1-type cytokines. This promotes a cell-mediated immune response.
Receptor-Mediated Signaling: Research suggests thymopentin may interact with Toll-like receptors (TLRs) and other pattern recognition receptors on immune cells, initiating signaling cascades that lead to NF-κB activation and subsequent immune gene expression.
Neuroendocrine-Immune Axis: There is evidence that thymopentin can influence the hypothalamic-pituitary-adrenal axis, potentially modulating the immune response through neuroendocrine pathways, although this mechanism is less defined.
Research Applications
Immunodeficiency Conditions: Research has investigated thymopentin for restoring immune competence in secondary immunodeficiencies associated with chronic infections, aging, or chemotherapy. Studies suggest it can increase CD4+ T-cell counts, improve T-cell responsiveness to antigens, and reduce infection frequency.
Autoimmune and Inflammatory Diseases: In models of rheumatoid arthritis and other autoimmune conditions, thymopentin has shown potential to modulate the aberrant immune response. It appears to help restore immune tolerance and reduce inflammatory cytokine production without causing generalized immunosuppression.
Oncology Support: As an adjunct to cancer therapy, research has explored thymopentin's role in mitigating chemotherapy-induced immunosuppression. It may help maintain immune surveillance and reduce the incidence of opportunistic infections during treatment.
Infectious Diseases: Studies in chronic viral infections, such as hepatitis B and recurrent herpes, have examined thymopentin's ability to enhance specific antiviral immune responses, particularly cytotoxic T-lymphocyte activity against infected cells.
Safety & Side Effects
From animal and human clinical studies, thymopentin is generally well-tolerated. The most commonly reported side effects are local reactions at the injection site, such as mild pain, redness, or swelling. Systemic side effects are rare but have included transient fatigue, dizziness, or mild gastrointestinal discomfort. No significant organ toxicity has been reported at therapeutic doses. Theoretical concerns, based on its immunomodulatory action, include the potential for exacerbating pre-existing autoimmune conditions or causing immune imbalance if dosed inappropriately, though these are not commonly observed. Anecdotal reports from research contexts are minimal and align with the mild profile observed in formal studies.
Dosage Information
This information is derived from published research studies only and is not intended for clinical guidance.
In research settings, thymopentin has been administered via subcutaneous injection. Typical research doses range from 0.5 mg to 5 mg per administration. In many clinical trials, a common regimen involved 1 mg administered subcutaneously daily for 7-14 days, followed by maintenance doses of 1 mg administered 2-3 times per week for several weeks or months. The specific dose, frequency, and duration are highly dependent on the research model and condition being studied.
References
Goldstein, G., Scheid, M.P., Boyse, E.A., Schlesinger, D.H., Van Wauwe, J. A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science. 1979.
Kouttab, N.M., Prada, M., Cazzola, P. Thymopentin modulates cytokine gene expression in the thymus and peripheral T lymphocytes. Immunopharmacology. 1994.
Barcellini, W., et al. In vivo immunomodulating effects of thymopentin in cancer patients. Cancer Immunology, Immunotherapy. 1988.
Wang, F., et al. Efficacy of thymopentin in treatment of chronic hepatitis B. World Journal of Gastroenterology. 2005.
Malaise, M.G., et al. Thymopentin in rheumatoid arthritis. A double-blind placebo controlled trial. Arthritis & Rheumatism. 1987.
Szekanecz, Z., et al. Immunomodulatory effects of thymopentin in vivo and in vitro. Immunology Letters. 1990.